Modulation of chemosensitivity through altered expression of cell cycle regulatory genes in cancer

Anti-Cancer Drugs

Volumn 8, Issue 10, 1997, Pages 903-910

  Hochhauser, Daniel ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Cell cycle; Chemosensitivity; Regulatory genes

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN D1; METHOTREXATE; PROTEIN P16; PROTEIN P53;

CANCER CHEMOTHERAPY; CELL CYCLE; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TARGETING; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REGULATOR GENE; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0031455518     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199711000-00001     Document Type: Review

References (80)

1. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
2. Hochhauser D, Harris AL. The role of topoisomerase IIα and β in drug resistance. Cancer Treat Rev 1993; 19: 181-94.
3. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994; 269: 787-90.
4. Bertino JR. Ode to methotrexate. J Clin Oncol 1993; 11: 5-14.
5. Reed JC, Miyashita T, Takayama S, et al. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996; 60: 23-32.
6. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anti-cancer agents. Cell 1993; 74: 957-67.
7. Lowe SW, Bodis S, McClatchley A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-10.
8. Fan S, El-Deiry WS, Bae I, et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 1994; 54: 5824-30.
9. Nelson WG, Kastan MB. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 1994; 14: 1815-23.
10. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
11. MacLachlan TK, Sang N, Giordano A. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 1995; 5: 127-56.
12. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91.
13. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-9.
14. Sherley JL. Guanine nucleotide biosynthesis is regulated by the cellular p53 concentration. J Biol Chem 1991; 266: 24815-28.
15. waf1/cip1 Genes Dev 1994; 8: 2817-30.
16. Attardi LD, Lowe SW, Brugarolas J, Jacks T. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J 1996; 15: 3693-701.
17. Ronen D, Schwartz D, Teitz Y, Goldfinger N, Rotter V. Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild-type p53 protein whereas differentiation of the cells is mediated by lower p53 levels. Cell Growth Different 1996; 7: 21-30.
18. Ramqvist T, Magnusson KP, Wang Y, Szekely L, Klein G, Wiman KG. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene 1993; 8: 1495-500.
19. Yang B, Stambrook PJ, Markowitz SD. Wild-type p53 demonstrates functional dominance in a human colon carcinoma cell line in which it induces reversible growth arrest. Clin Cancer Res 1996; 2: 1639-47.
20. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-8.
21. Wang JYJ, Knudsen ES, Welch PJ. The retinoblastoma tumor suppressor protein. Adv Cancer Res 1994; 64: 25-85.
22. Herwig S, Strauss M. The retinoblastoma protein: a master regulator of cell cycle, differentiation and apoptosis. Eur J Biochem 1997; 246: 581-601.
23. Schilling LJ, Farnham PJ. Transcriptional regulation of the dihydrofolate reductase/rep-3 locus. Crit Rev Enkaryot Gene Expr 1994; 4: 19-53.
24. Cordon-Cardo C. Mutation of cell cycle regulators; biological and clinical implications for human neoplasia. Am J Pathol 1995; 147: 545-60.
25. Lukas J, Aagaard L, Strauss M, Bartek J. Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res 1995; 55: 4818-23.
26. Bartkova J, Lukas J, Guldberg P, et al. The p16-cyclin D/ Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996; 56: 5475-83.
27. Schauer IE, Siriwardana S, Langan TA, Sclafani RA. Cyclin D1 overexpression vs retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci USA 1994; 91: 7827-31.
28. Shapiro GI, Edwards CD, Kobzik L, et al. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 1995; 55: 505-9.
29. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88: 1442-55.
30. Lutzker SG, Levine AJ. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat Med 1996; 2: 804-10.
31. Banerjee D, Lenz H-J, Schnieders B, et al. Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress. Cell Growth Afferent 1995; 6: 1405-13.
32. Belluco C, Guillem JG, Kemeny N, et al. p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 1996; 14: 2696-701.
33. Fan S, Smith ML, Rivet DJ, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995; 00: 1649-54.
34. Righetti SC, Della Torre G, Pilotti S, et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996; 56: 689-93.
35. Rusch V, Klimstra D, Venkatraman E, et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995; 55: 5038-42.
36. 2/M arrest and apoptosis. Nat Med 1996; 2: 72-9.
37. Safran H, King T, Choy H, et al. p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma. Cancer 1996; 78: 1203-10.
38. Miller CW, Simon K, Aslo A, et al. p53 mutations in human lung tumors. Cancer Res 1992; 52: 1695-8.
39. Aas T, Borresen A-L, Geisler S, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2: 811-4.
40. Sandri MI, Isaacs RJ, Ongkeko WM, et al. p53 regulates the minimal promoter of the human topoisomerase II alpha gene. Nucleic Acids Res 1996; 24: 4464-70.
41. Wang Q, Zambetti GP, Suttle DP. Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor. Mol Cell Biol 1997; 17: 389-97.
42. Fry AM, Chresta CM, Davies SM, et al. Relationship between topoisomerase II level and chemosensitivity in human tumour cell lines. Cancer Res 1991; 51: 6592-5.
43. Chin K-V, Ueda K, Pastan I, Gottesman MM. Modulation of the activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992; 255: 459-62.
44. Goldsmith ME, Gudas JM, Schneider E, Cowan KH. Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J Biol Chem 1995; 270: 1894-8.
45. Schneider J, Rubio MP, Barbazan MJ, Rodriguez-Escudero FJ, Seizinger BR, Castresana JS. P-glycoprotein, HER-2/ neu, and mutant p53 expression in human gynecologic tumors. J Natl Cancer Inst 1994; 86: 850-5.
46. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. Effects of an Rb mutation in the mouse. Nature 1992; 359: 295-300.
47. Haas-Kogan DA, Kogan SC, Levi D, et al. Inhibition of apoptosis by the retinoblastoma gene product. EMBO J 1995; 14: 461-72.
48. Li WW, Fan J, Hochhauser D, et al. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci USA 1995; 92: 10436-40.
49. Bartkova J, Lukas J, Strauss M, Bartek J. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 1995; 10: 775-8.
50. 1 phase in rodent fibroblasts. Genes Dev 1993; 7: 1559.
51. 1/S phase by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 1994; 14: 1669.
52. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 1994; 91: 709.
53. Arber N, Doki Y, Han EK, et al. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 1997; 57: 1569-74.
54. Han EK, Sgambato A, Jiang W, et al. Stable overexpression of cyclin D1 in a human mammary epithelial cell line prolongs the S-phase and inhibits growth. Oncogene 1995; 10: 953-61.
55. Zhou P, Jiang W, Zhang YJ, et al. Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene 1995; 11: 571-80.
56. Hochhauser D, Schnieders B, Ercikan-Abali E, et al. Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line. J Natl Cancer Inst 1996; 88: 1269-75.
57. 1 regulation in human head and neck cancer. Cancer Res 1995; 55: 949-56.
58. Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 1995; 55: 975-8.
59. Tomida A, Suzuki H, Kim HD, Tsuruo T. Glucose-regulated stresses cause decreased expression of cyclin D1 and hypophosphorylation of retinoblastoma protein in human cancer cells. Oncogene 1996; 13: 2699-705.
60. ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA 1995; 92: 6289-93.
61. Stone S, Dayananth P, Kamb A. Reversible, p16-mediated cell cycle arrest as protection from chemotherapy. Cancer Res 1996; 56: 199-202.
62. Terry LA, Boyd J, Alcorta D, et al. Mutational analysis of the p21/WAF1/CIP1/SDI1 coding region in human tumor cell lines. Mol Carcinog 1996; 16: 221-8.
63. 1 checkpoint control. Cell 1995; 82: 675-84.
64. Waldman T, Lengauer C, Kinzler KW, Vogelstein H. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996; 381: 713-6.
65. McDonald ER, III, Wu GS, Waldman T, El-Deiry WS. Repair defect in p21 WAF1/CIP1 -/-human cancer cells. Cancer Kes 1996; 56: 2250-5.
66. Sheikh MS, Chen YQ, Smith ML, Fornace AJ Jr. Role of p21Waf1/Cip1/Sdi1 in cell death and DNA repair as studied using a tetracycline-inducible system in p53-deficient cells. Oncogene 1997; 14: 1875-82.
67. waf1 leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells. Cancer Res 1997; 57: 2193-9.
68. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997; 3: 222-5.
69. St Croix H, Florenes VA, Rak JW, et al. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 1996; 2: 1204-10.
70. Nevins JR. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992; 258: 424.
71. Johnson DG, Cress WD, Jakoi L, Nevins JR. Oncogenic capacity of the E2F1 gene. Proc Natl Acad Sci USA 1994; 91: 12823-7.
72. Singh P, Wong SH, Hong W. Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. EMBO J 1994; 13: 3329-38.
73. Qin XQ, Livingston DM, Kaelin WG, Adams PD. Deregulated transcription factor E2F-1 expression leads to S phase entry and p53-mediated apoptosis. Proc Natl Acad Sci USA 1994; 91: 10918-22.
74. Nip J, Strom DK, Fee BE, Zambetti G, Cleveland JL, Hiebert SW. E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Mol Cell Biol 1997; 17: 1049-56.
75. Saito M, Helin K, Valentine MB, et al. Amplification of the E2F1 transcription factor gene in the HEL erythroleukemia cell line. Genomics 1995; 25: 130-8.
76. Yamasaki L, Jacks T, Bronson E, Goillot E, Harlow E, Dyson NJ. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 1996; 85: 537-48.
77. 2 arrest in Chinese hamster ovary cells. Cancer Res 1990; 50: 3761-6.
78. 2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res 1996; 56: 4430-7.
79. Ongkeko W, Ferguson DJ, Harris AL, Norbury C. Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage. J Cell Sci 1995; 108: 2897-904
80. 2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996; 88: 956-65.